Intra-articular Injection of MSC-derived Exosomes in Knee Osteoarthritis (ExoOA-1)

Summary

The study aim to evaluate safety of exosomes (sEVs) from allogeneic mesenchymal stromal cells delivered by an intra-articular injection in the knee of patients with mild to moderate symptomatic osteoarthritis. The sEVs will be produced in a GMP-facility. We expect to enrolle 10 patients in this phase 1 trial and the follow-up will be up to 12 months.

Timeline

Start

2021-10-05

Primary completion

2023-04-05

Completion

2023-10-05

Drugs

Indications